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Introduction: Interindividual variability in drug efficacy and toxicity 
can be partly attributed to genetic variation in metabolic enzymes, 
such as CYP2D6. The administration of probe substrates such as 
debrisoquine has been widely used in vivo to phenotype CYP2D6 
metabolic activity. Recently, it was revealed that debrisoquine is also 
a substrate for the OCT1 uptake transporter. Therefore, the principal 
focus of this study was to analyze the misphenotyping that may arise 
in the complex situation, where drugs are substrates to both poly-
morphic enzymes and hepatic uptake transporters.
Patients (or Materials) and Methods: A physiologically based phar-
macokinetic modeling and simulation approach was carried out using 
the Simcyp Simulator (v12). A virtual study population (n = 1000) 
was generated including extensive, poor, and ultrarapid CYP2D6 
metabolizers (86.5%, 8.2%, and 5.3% of the population, respec-
tively). CYP2D6 activity was phenotyped using dextromethorphan 
as a probe substrate and monitoring indirect metrics such as the 
urinary recovery or plasma area under the curve metabolite/drug 
(dextrorphan/dextromethorphan) ratios. Multimodality in the fre-
quency distribution of these metrics in the study population was 
assessed with the NTV (normal test variable) graphical method. 
Using a permeability-limited liver model and gradually decreasing the 
influx of the probe substrate into the liver, we investigated the effects 
of this decrease on the modality of the metrics frequency distribution.
Results: Phenotyping successfully identified a clear multimodal fre-
quency distribution in the study population with regard to CYP2D6 
activity, when no hepatic permeability restrictions are applied to the 
probe substrate. However, when the uptake of the probe substrate 
into the liver is not passive but mainly transporter-mediated, the 
multimodality on the frequency distribution was clearly affected, 
confounding the distinction between the poor and extensive metabo-
lizers. Specifically, when the contribution of the active uptake to 
total uptake was > 90%, multimodality was distorted to a unimodal 
frequency distribution.
Conclusion: In conclusion, the findings suggest that when using 
a probe drug to phenotype the activity of a metabolic enzyme the 
hepatic permeability characteristics of the compound should be 
also considered. When uptake of the probe drug is predominately 
transporter mediated, influx into hepatocytes and not metabolism 
is the step that mostly contributes to the phenotype. Taking also 
into account that uptake transporters can also be polymorphically 
expressed the possibility that transporter variation can produce a 
flawed perception of enzyme activity should not be neglected.
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Introduction: Genetic variants of CYP2D6 may have an effect on 
drug efficiency and toxicity; those variants have not been extensively 
evaluated in Mexican indigenous populations. We determined the 
CYP2D6 allele distribution Amerindian from northwest of Mexico.
Patients (or Materials) and Methods: A total of 508 Amerindians 
from 8 ethnic groups were evaluated through both (1) genotyping of 
CYP2D6*2, *3, *4, *6, *10, *17, *29, *35, *41, and copy number 
by real time-PCR and (2) amplification of entire CYP2D6 gene by 
XL-PCR for CYP2D6*5 and multiplication alleles.
Results: The CYP2D6*2 was the most frequent in these populations 
(0.05–0.28). The CYP2D6*4 was found with the highest values in 
Seris and Tarahumaras (0.21 and 0.11, respectively) and in Mayos, 
Huicholes, Guarijíos, Coras, and Tepehuanos the frequencies were 
of 0.08, 0.07, 0.03, 0.01, and 0.003, respectively. CYP2D6*5 was 
observed in the Tepehuanos (0.004), Mexicaneros (0.013), Coras 
(0.012), and Tarahumaras (0.034). The CYP2D6*6 was presented 
only in Mayos (0.034) and the CYP2D6*10 only in Tarahumaras 
(0.007).CYP2D6*41 allele was identified in Tepehuanos (0.004), 
Mayos (0.03), Tarahumaras (0.04), and Coras (0.01). The 
CYP2D6*3, *17, *35 and *29 variants were not detected. The fre-
quency of multiplications of functional alleles was in a range of 0.043 
to 0.10. Only 1 Tarahumara subject (1.35%) was homozygous for 
2 inactive alleles (*4/*5).
Conclusion: Our data share a CYP2D6 polymorphic pattern similar 
to other studies in Amerindian groups. The information obtained 
may be useful for generating drug therapy strategies tailored to the 
indigenous population of Mexico.
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Introduction: Major depressive disorder (MDD) is a prevalent and 
severe psychiatric disease with a highly variable treatment response 
and a poorly understood pathogenesis. The present study is focused 
on to find out the C3435T polymorphism of ABCB1 influence on 
susceptibility to depression and clinical response to citalopram.
Patients (or Materials) and Methods: Patients (n = 54) who met 
the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition-IV criteria for MDD were enrolled the study. Control group 
consisted of unrelated volunteers (n = 70). All patients had affirmed 
for once a day administration of citalopram at 8:00 to 9:00 pm during 
the study. Protocol visits were completed at baseline, 1st, 2nd, 4th, 
and 6th weeks. The clinical response to citalopram was evaluated 
by psychiatrists with 17-item Hamilton Rating Scale for Depression 
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(HAM-D). Blood samples were taken at 8:00 to 9:00 am (almost 12 
hours after the drug administration) at 4th week for measurement 
steady-state drug concentrations and genotyping. Genotyping for the 
ABCB1 gene 3435C> T (exon 26) polymorphism was performed by 
PCR/RFLP assays. Serum levels of citalopram were determined by 
high-performance liquid chromatography.
Results: We found statistically significant differences between the 
frequency of C allele for 3435C/T of patients and controls (p= 0.020) 
(Table). The efficacy of citalopram was examined for genotypes in 
2 ways comparisons as responder/nonresponder groups according 
to HAM-D scores at 6th week and also HAM-D scores at 1st, 2nd, 
and 4th weeks. There was no significant difference for 3435C/T 
between the responders and nonresponders (P = 1.000). According 
to 3435C/T genotype HAM-D scores were not statistically significant 
(F = 1.280, P = 0.279).
Table.  Genotype and allele frequencies of ABCB1 3435C/T 
polymorphism in MDD and control groups.
Group Genotype distribution, n (%) Allele frequency, n (%)
C/C C/T T/T C T
MDD (n = 56) 19 (35%) 22 (41%) 13 (24%) 60 (56%) 48 (44%)
Control (n = 70) 8 (11%) 41 (59%) 21 (30%) 57 (41%) 83 (59%)
χ 2= 10.199, df= 2, 
p= 0.006*
χ 2= 5.389, df= 1, 
p= 0.020*
Conclusion: Our results suggested that C3435T polymorphism in 
the ABCB1 gene may be an indicator of the susceptibility to major 
depression but not likely treatment response to citalopram in Turkish 
population.
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Introduction: CYP2D6 differences have already been demonstrated 
within Latin-American populations by the Iberoamerican Network 
of Pharmacogenetic CEIBA Consortium. However, until now, no 
other investigations have been developed within Costa Rica’s popu-
lation, which is of interest becuase this population has a trihybrid 
component ancestry. The present study was aimed to determine the 
frequency of CYP2D6 predicted phenotype within 3 Costa Rican 
groups with different ethnic backgrounds and to describe CYP2D6 
genotypes and allele frequencies compared with other Latin-
American populations.
Patients (or Materials) and Methods: Three hundred eighty-five 
individuals were included in the study (139 Mestizo/CRM, 197 
Amerindians/AM, and 49 Afro-Caribbeans/AC). XL-PCR and real-
time PCR were performed to determine CYP2D6 genotypes. The 
CYP2D6 variant alleles *2, *3, *4, *5, *6, *10, *17, *29, *35 and 
*41 were determined.
Results: The highest frequencies of UMs (10.1%) and PMs 
(10.2%) were found in the CRM and AM population, respec-
tively. Multiplication of active genes (5.4%) were responsible for 
the high frequency of UMs in CRM population, and the pres-
ence of CYP2D6*4 (22.6%) for PMs in AM group. As expected, 
CYP2D6*17 and *29 were higher in AC group, 18.4 and 11.2% 
respectively. However, *10 was lower in the AM population (0.3%).
Conclusion: CYP2D6 predicted phenotypes vary for UMs from 10.1 
to 3.6% and PMs from 10.2 to 1.4%, among 3 Costa Rican groups 
with different ethnic background. In addition, CYP2D6 genotype 
and allele frequencies of the Costa Rican population studied differ 
in comparison to other Latin-American populations.
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Introduction: Losartan has been suggested as a selective probe for 
CYP2C9 metabolic activity. Recently, a single nucleotide polymor-
phism (SNP) IVS8-109A> T linked to SNPs in the 5’-UTR, exon 1 
and intron 1 of the CYP2C9 gene1 has been described in association 
with a higher CYP2C9 losartan metabolic ratio (MR) in healthy 
Swedes.2 The aim of this study was to examine whether there is a 
relationship between the CYP2C9 polymorphism IVS8-109A> T and 
the losartan/E3174 MR, in a previously studied healthy population 
of Ecuadorians.3
Patients (or Materials) and Methods: The CYP2C9 IVS8-109A> T 
polymorphism was analyzed in 161 unrelated Ecuadorian subjects 
using a specific PCR-RFLP method.2 These participants had been 
previously genotyped for CYP2C9 alleles *2, *3, *4, *5 and *6 and 
phenotyped with a single oral dose of 25 mg losartan,3 and all of 
them were CYP2C9*1/*1.
Results: The frequency of the allelic IVS8-109A> T polymorphism 
in this study was 0.23. The urinary losartan/E3174 ratio was sig-
nificantly higher (p = 0.024; Student t test) in subjects with the A/A 
(IVS8-109) genotype (mean [SD], 5.1 [6.6]; n = 95) than in subjects 
with T/T (2.3 [3.7]; n = 8). Present results show that the IVS8-109T 
allele is associated with a lower CYP2C9 MR in this healthy popu-
lation of Ecuadorian subjects, which is in disagreement with previ-
ous findings in healthy Swedes that reported the IVS8-109T allele in 
association with a higher CYP2C9 MR.2
Conclusion: This study shows that the SNP IVS8-109T allele is asso-
ciated with a lower CYP2C9 MR, but further investigations need to 
be carried out to establish a molecular explanation for ultra-rapid 
CYP2C9- catalyzed metabolism.
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